These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 19554441)

  • 1. Hyponatremia in heart failure: the role of arginine vasopressin and diuretics.
    Rosner MH
    Cardiovasc Drugs Ther; 2009 Aug; 23(4):307-15. PubMed ID: 19554441
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hyponatremia in heart failure: the role of arginine vasopressin and its antagonism.
    Rosner MH; Ronco C
    Congest Heart Fail; 2010 Jul; 16 Suppl 1():S7-14. PubMed ID: 20653716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Arginine vasopressin receptor antagonists (vaptans): pharmacological tools and potential therapeutic agents.
    Veeraveedu PT; Palaniyandi SS; Yamaguchi K; Komai Y; Thandavarayan RA; Sukumaran V; Watanabe K
    Drug Discov Today; 2010 Oct; 15(19-20):826-41. PubMed ID: 20708094
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AVP receptor antagonists in patients with CHF.
    Kumar SK; Mather PJ
    Heart Fail Rev; 2009 Jun; 14(2):83-6. PubMed ID: 18766439
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overview of vasopressin receptor antagonists in heart failure resulting in hospitalization.
    De Luca L; Orlandi C; Udelson JE; Fedele F; Gheorghiade M
    Am J Cardiol; 2005 Dec; 96(12A):24L-33L. PubMed ID: 16399090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vasopressin and Vasopressin Antagonists in Heart Failure.
    Vishram-Nielsen JK; Gustafsson F
    Handb Exp Pharmacol; 2017; 243():307-328. PubMed ID: 28432473
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treating hyponatremia in heart failure.
    Goldsmith SR
    Curr Cardiol Rep; 2006 May; 8(3):204-10. PubMed ID: 17552085
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tolvaptan, an orally active vasopressin V(2)-receptor antagonist - pharmacology and clinical trials.
    Miyazaki T; Fujiki H; Yamamura Y; Nakamura S; Mori T
    Cardiovasc Drug Rev; 2007; 25(1):1-13. PubMed ID: 17445084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential roles of vaptans in heart failure: experience from clinical trials and considerations for optimizing therapy in target patients.
    Lin TE; Adams KF; Patterson JH
    Heart Fail Clin; 2014 Oct; 10(4):607-20. PubMed ID: 25217436
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Vasopressin antagonists in treatment of hyponatremia].
    Olszewski W; Głuszek J
    Pol Arch Med Wewn; 2007 Aug; 117(8):356-62. PubMed ID: 18018383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypervolemic Hyponatremia in Heart Failure.
    Davila CD; Udelson JE
    Front Horm Res; 2019; 52():113-129. PubMed ID: 32097923
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment options for hyponatremia in heart failure.
    Goldsmith SR
    Heart Fail Rev; 2009 Jun; 14(2):65-73. PubMed ID: 18777208
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Hyponatremic hypervolemia in heart failure--the hot spot for vasopressin receptor antagonists?].
    Dabrowska MD; Krysiak R; Okopień B
    Wiad Lek; 2012; 65(1):19-30. PubMed ID: 22827112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Hyponatremia in heart failure: physiopathology and pharmacological approach].
    Robledo GG; Cantillo DS; Comín Colet J
    Endocrinol Nutr; 2010 May; 57 Suppl 2():10-4. PubMed ID: 21130957
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The potential role for lixivaptan in heart failure and in hyponatremia.
    Zmily HD; Khan NS; Daifallah S; Ghali JK
    Expert Opin Investig Drugs; 2011 Jun; 20(6):831-48. PubMed ID: 21548825
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lixivaptan, a non-peptide vasopressin V2 receptor antagonist for the potential oral treatment of hyponatremia.
    Ghali JK; Zmily HD; Farah JO; Daifallah S
    IDrugs; 2010 Nov; 13(11):782-92. PubMed ID: 21046526
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BSC1 inhibition complements effects of vasopressin V2 receptor antagonist on hyponatremia in SIADH rats.
    Kazama I; Hatano R; Michimata M; Suzuki K; Arata T; Suzuki M; Miyama N; Sato A; Satomi S; Ejima Y; Sasaki S; Matsubara M
    Kidney Int; 2005 May; 67(5):1855-67. PubMed ID: 15840033
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vasopressin dysregulation: hyponatremia, fluid retention and congestive heart failure.
    LeJemtel TH; Serrano C
    Int J Cardiol; 2007 Aug; 120(1):1-9. PubMed ID: 17346825
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The clinical effects of vasopressin receptor antagonists in heart failure.
    Gheorghiade M
    Cleve Clin J Med; 2006 Jun; 73 Suppl 2():S24-9; discussion S30-3. PubMed ID: 16786910
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vasopressin receptor antagonists: potential indications and clinical results.
    Arai Y; Fujimori A; Sudoh K; Sasamata M
    Curr Opin Pharmacol; 2007 Apr; 7(2):124-9. PubMed ID: 17292670
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.